Vivian Fonseca
Dados Biográficos
| ID | 5545007 |
|---|---|
| NOME | Vivian Fonseca |
| PRENOMES | Vivian |
| SOBRENOME | Fonseca |
| ASSINATURA | FONSECA V |
| AFILIAÇÕES | Section of Endocrinology, Tulane University Health Sciences Center, New Orleans |
| ORCID | 0000-0002-3381-7151 |
| VERIFICADO | Sim |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2023 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2026 |
| ÍNDICE H | 0 |
Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes
Background: This study aimed to evaluate the long-term cost-effectiveness of insulin glargine/lixisenatide injection (iGlarLixi) vs. insulin degludec/insulin aspart (IDegAsp) in individuals with poorly controlled type 2 diabetes in China. Methods: This study employed the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model to simulate 20-year clinical and economic outcomes from the perspective of the Chinese healthcare sy…
The Impact of Reimbursement for Non–Face-to-Face Chronic Care Management on Comprehensive Metabolic Biomarkers Among Multimorbid Patients With Type 2 Diabetes
AIMS: We evaluated the impact of reimbursement for non-face-to-face chronic care management (NFFCCM) on comprehensive metabolic risk factors among multimorbid Medicare beneficiaries with type 2 diabetes in Louisiana. MATERIALS AND METHODS: We implemented a propensity score method to obtain comparable treatment (n=1501 with NFFCCM) and control (n=17,524 without NFFCCM) groups. Patients with type 2 diabetes were extracted from the electronic health…
Sem obras proeminentes nesta página.
The Impact of Reimbursement for Non–Face-to-Face Chronic Care Management on Comprehensive Metabolic Biomarkers Among Multimorbid Patients With Type 2 Diabetes
AIMS: We evaluated the impact of reimbursement for non-face-to-face chronic care management (NFFCCM) on comprehensive metabolic risk factors among multimorbid Medicare beneficiaries with type 2 diabetes in Louisiana. MATERIALS AND METHODS: We implemented a propensity score method to obtain comparable treatment (n=1501 with NFFCCM) and control (n=17,524 without NFFCCM) groups. Patients with type 2 diabetes were extracted from the electronic health…
Cost-effectiveness of iGlarLixi vs. IDegAsp in individuals with type 2 diabetes
Background: This study aimed to evaluate the long-term cost-effectiveness of insulin glargine/lixisenatide injection (iGlarLixi) vs. insulin degludec/insulin aspart (IDegAsp) in individuals with poorly controlled type 2 diabetes in China. Methods: This study employed the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model to simulate 20-year clinical and economic outcomes from the perspective of the Chinese healthcare sy…
Diabetes mellitus (2 obras) · Diabetes Treatment and Management (2 obras) · Health care (2 obras) · Type 2 diabetes (2 obras) · Blood pressure (1 obras) · Body mass index (1 obras) · Chronic Disease Management Strategies (1 obras) · Clinical trial (1 obras) · Cohort (1 obras) · Diabetes Management and Education (1 obras)